Prevention of Episodic Migraine with AMG 334, a Human Anti-Calcitonin Gene-Related Peptide Receptor Monoclonal Antibody: Phase 2 Study Results and 52-Week Analysis of Open-Label Extension (I3.001)

Conclusions:AMG334 70-mg demonstrated sustained efficacy in prevention of episodic migraine. The safety/tolerability profile of AMG334 in this phase 2 study supports continued development.Disclosure: Dr. Lenz hold stock and/or stock options in Amgen. Dr. Dodick has received personal compensation for activities with Allergan, Amgen, Alder, Merck Serono, ENeuro, Eli Lilly, Autonomic Technologies, Boston Scientific, Novartis, Tonix, Teva, Trigemina as a consultant and for activities with SAGE Publishing, Dr. Goadsby has received personal compensation for activities with Allergan, Inc., eNeura, Autonomic Technologies, Amgen, AlderBio, Pfizer, DrReddy, Zosano, Colucid, Eli-Lilly, Avanir, Gore, Heptares, Nupathe, Teva, Cipla, Ajinomoto, Akita, Wells Fargo, E Dr. Silberstein's employer receives research support from Allergan, Inc.; Amgen; Cumberland Pharmaceuticals, Inc.; ElectroCore Medical, LLC; Labrys Biologics; Eli Lilly and Company; Merz. Dr. Reuter has received personal compensation for activities with Amgen, Co-Lucid, Allergan, Electrocore, and Autonomic Technologies. Dr. Ashina has received research support from ATI and Amgen. Dr. Saper has received research support from Allergan, Merck, St. Jude Medical, Eli Lilly, Pfizer, Vanda, Forest Research Institute, Johnson & Johnson, Endo Pharmaceuticals Inc., Astellas, Bristo-Meyers Squibb Company, SK Lifesciences, Optinose, and Nu Pa Dr. Cady has received personal compensation for activities with Aerocrine, Allergan, Avanir,...

Source: Neurology - April 3, 2016 Category: Neurology Authors: Lenz, R., Dodick, D., Goadsby, P., Silberstein, S., Reuter, U., Ashina, M., Saper, J., Cady, R., Zhang, F., Trotman, M.-L., Dietrich, J., Sun, H. Tags: New and Emerging Therapeutic Options in Migraine and Other Headache Disorders Data Blitz Presentations Source Type: research